Page last updated: 2024-10-30

leflunomide and Adenocarcinoma Of Kidney

leflunomide has been researched along with Adenocarcinoma Of Kidney in 1 studies

Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, Y1
Huang, Q1
Zhou, H1
Wang, Y1
Hu, X1
Li, T1

Other Studies

1 other study available for leflunomide and Adenocarcinoma Of Kidney

ArticleYear
Inhibition of canonical WNT/β-catenin signaling is involved in leflunomide (LEF)-mediated cytotoxic effects on renal carcinoma cells.
    Oncotarget, 2016, Aug-02, Volume: 7, Issue:31

    Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; beta Catenin; Carcinoma, Renal Cell; Cell Line

2016